NASDAQ •
Healthcare •
Biotechnology •
Quote as of 04/24/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization4,549.87 mln
Float311 mln
Earnings Date05/13/2026
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-2.73
Likely reliable
Relative Strength
29
/ 100
Underperforming
Debt / Equity
1.61
High leverage
Pre-Tax Margin
5%
Low margin
ROE
-12.36
Negative
Business Description
Amicus Therapeutics is a biotechnology company founded in 2002 and based in Princeton, New Jersey, that works to create and bring to market treatments for rare and serious diseases. Its key products include Galafold, a once-daily pill for adults with Fabry disease, and Pombiliti + Opfolda, a two-part treatment for adults with late-onset Pompe disease. The company also has a drug candidate in late-stage clinical trials targeting a rare kidney condition called focal segmental glomerulosclerosis. Amicus works alongside partners GlaxoSmithKline and Dimerix Limited to develop and sell its treatments in the United States and around the world.
